Artelo Biosciences, Inc. (NASDAQ:ARTL) Short Interest Update

Artelo Biosciences, Inc. (NASDAQ:ARTL) was the recipient of a significant decrease in short interest during the month of May. As of May 15th, there was short interest totaling 37,850 shares, a decrease of 39.5% from the April 30th total of 62,523 shares. Based on an average daily volume of 871,254 shares, the short-interest ratio is currently 0.0 days. Currently, 1.8% of the shares of the stock are short sold.

Analyst Ratings Changes

ARTL has been the topic of several recent analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Artelo Biosciences in a research note on Friday, March 27th. Wall Street Zen raised Artelo Biosciences from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 16th. Two research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Reduce” and an average target price of $54.00.

Artelo Biosciences Stock Performance

Shares of NASDAQ ARTL opened at $1.41 on Thursday. The firm has a 50 day moving average price of $3.94 and a two-hundred day moving average price of $4.45. The stock has a market cap of $3.29 million, a P/E ratio of -0.04 and a beta of -0.13. Artelo Biosciences has a 52-week low of $1.19 and a 52-week high of $85.80.

Artelo Biosciences (NASDAQ:ARTL) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($4.00) earnings per share for the quarter, missing the consensus estimate of ($0.78) by ($3.22).

About Artelo Biosciences

Artelo Biosciences, Inc is a clinical-stage biopharmaceutical company focused on the development of novel small-molecule therapies for pain, inflammation, ocular and cardiometabolic disorders. The company leverages a proprietary drug delivery and targeting platform designed to enhance the safety and efficacy profiles of well-characterized active pharmaceutical ingredients. Artelo’s approach is centered on repurposing and optimizing therapeutic molecules to address significant unmet medical needs, with particular emphasis on improving patient tolerability and clinical outcomes.

The company’s lead program, AB101, is an orally bioavailable ion channel modulator in development for neuropathic pain conditions including post-herpetic neuralgia.